Uniwersyteckie Centrum Medycyny Morskiej I Tropikalnej
- Address
- Ul. Powstania Styczniowego 9b, 81-519 Gdynia, Poland
Uniwersyteckie Centrum Medycyny Morskiej I Tropikalnej - Cardiovascular Research Center
The Uniwersyteckie Centrum Medycyny Morskiej I Tropikalnej is a leading research institution specializing in advanced cardiovascular therapeutics and heart failure management. The center demonstrates particular expertise in investigating novel pharmacological interventions for acute heart failure and complex cardiovascular conditions, with a focus on improving patient outcomes through innovative treatment strategies.
- SGLT-2 inhibitors (dapagliflozin and empagliflozin) in acute and decompensated heart failure across all ejection fraction phenotypes
- Cardiovascular outcomes research including mortality and hospitalization endpoints
- Neuropsychiatric aspects of heart failure, including depression and anxiety management in patients with preserved ejection fraction
The center's research portfolio reflects a comprehensive approach to heart failure treatment, investigating both pharmacological interventions and psychosomatic factors that influence cardiovascular health. Their clinical trials encompass diverse patient populations regardless of diabetes status or ejection fraction classification (HFrEF, HFmEF, HFpEF), demonstrating commitment to personalized medicine and evidence-based cardiovascular care. The center also explores the relationship between endothelial dysfunction, biomarkers, and psychological comorbidities in heart failure patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Anthos Therapeutics Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Medical University Of Gdansk3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersyteckie Centrum Medycyny Morskiej I Tropikalnej
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 1 | Unknown | 2023-10-31 | 2023-10-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.